The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | DREAMM-2: Belantamab mafodotin for R/R myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses DREAMM-2 (NCT03525678), an open-label, two-arm, Phase II study investigating belantamab mafodotin for relapsed or refractory (R/R) multiple myeloma. Belantamab mafodotin is an immunoconjugate targeting B-cell maturation antigen and has shown single-agent activity in the Phase 1 DREAMM-1 study in heavily pre-treated patients with R/R multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Sagar Lonial, MD, has done consultancy work for Takeda, Celgene, BMS, Janssen, GSK, Abbvie, Novartis and Janssen; and has been a member of a board of directors for TG Therapeutics.
